Download MendeleyOptimization of a series of novel, potent and selective Macrocyclic SYK inhibitors.
Grimster, N.P., Gingipalli, L., Balazs, A., Barlaam, B., Boiko, S., Boyd, S., Dry, H., Goldberg, F.W., Ikeda, T., Johnson, T., Kawatkar, S., Kemmitt, P., Lamont, S., Lorthioir, O., Mfuh, A., Patel, J., Pike, A., Read, J., Romero, R., Sarkar, U., Sha, L., Simpson, I., Song, K., Su, Q., Wang, H., Watson, D., Wu, A., Zehnder, T.E., Zheng, X., Li, S., Dong, Z., Yang, D., Song, Y., Wang, P., Liu, X., Dowling, J.E., Edmondson, S.D.(2023) Bioorg Med Chem Lett 91: 129352-129352
- PubMed: 37270074 Search on PubMed
- DOI: https://doi.org/10.1016/j.bmcl.2023.129352
- Primary Citation Related Structures:
8BI2 - PubMed Abstract:
Spleen tyrosine kinase (SYK) is a non-receptor cytoplasmic kinase. Due to its pivotal role in B cell receptor and Fc-receptor signalling, inhibition of SYK has been a target of interest in a variety of diseases. Herein, we report the use of structure-based drug design to discover a series of potent macrocyclic inhibitors of SYK, with excellent kinome selectivity and in vitro metabolic stability. We were able to remove hERG inhibition through the optimization of physical properties, and utilized a pro-drug strategy to address permeability challenges.
- Oncology R & D, AstraZeneca, Waltham, USA. Electronic address: neil.grimster@astrazeneca.com.
Organizational Affiliation:
